Toremifene Citrate
Toremifene Citrate structure
|
Common Name | Toremifene Citrate | ||
|---|---|---|---|---|
| CAS Number | 89778-27-8 | Molecular Weight | 598.083 | |
| Density | 1.045g/cm3 | Boiling Point | 535.1ºC at 760 mmHg | |
| Molecular Formula | C32H36ClNO8 | Melting Point | 158-164ºC | |
| MSDS | Chinese USA | Flash Point | 277.4ºC | |
| Symbol |
GHS05, GHS07, GHS09 |
Signal Word | Danger | |
|
Use of SERMs for treatment in postmenopausal women
J. Steroid Biochem. Mol. Biol. 142 , 142-54, (2014) • FDA approved selective estrogen receptor modulators (SERMs) prevent and treat breast cancer, osteoporosis and dyspareunia. • SERMs have varying agonist and antagonist activities at the level of the estrogen receptor (ER) in target tissues. • Targeted agonis... |
|
|
Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Biochim. Biophys. Acta 1831(12) , 1657-64, (2013) Acid ceramidase (AC), EC 3.5.1.23, a lysosomal enzyme, catalyzes the hydrolysis of ceramide to constituent sphingoid base, sphingosine, and fatty acid. Because AC regulates the levels of pro-apoptotic ceramide and mitogenic sphingosine-1-phosphate, it is cons... |
|
|
Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
J. Clin. Oncol. 31(5) , 523-9, (2013) Prostate cancer (PCa) prevention remains an appealing strategy for the reduction of overtreatment and secondary adverse effects. We evaluated the efficacy of toremifene citrate 20 mg in PCa prevention among men with isolated high-grade prostatic intraepitheli... |
|
|
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
J. Urol. 189(1 Suppl) , S45-50, (2013) Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year peri... |
|
|
Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.
J. Urol. 186(6) , 2239-44, (2011) Androgen deprivation therapy is associated with an increased fracture risk. In a recent phase III trial toremifene significantly decreased vertebral fractures in men on androgen deprivation therapy. Similar to other selective estrogen receptor modulators, tor... |
|
|
Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics.
Drug Metab. Dispos. 40(6) , 1210-5, (2012) Toremifene (TOR) is a selective estrogen receptor modulator used in adjuvant therapy for breast cancer and in clinical trials for prostate cancer prevention. The chemical structure of TOR differs from that of tamoxifen (TAM) by the presence of a chlorine atom... |
|
|
Evaluation of the genotoxicity of tamoxifen in the liver and kidney of F344 gpt delta transgenic rat in 3-week and 13-week repeated dose studies.
Toxicology 312 , 56-62, (2013) Transgenic rat gene mutation assays can be used to assess genotoxicity of chemicals in target organs for carcinogenicity. Mutations in transgenes are genetically neutral and accumulate during a treatment period; thus, the assays are suitable for assessment of... |
|
|
Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review.
Colorectal Dis. 13(12) , e388-95, (2011) The treatment of desmoid tumours (DTs) is controversial. Anti-oestrogen therapy has frequently been used, but clear information of its efficacy is lacking. In this systematic review we have undertaken a comprehensive analysis to assess the effectiveness of an... |
|
|
Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.
Int. J. Cancer 132(6) , 1475-85, (2013) We investigated the in vitro metabolism and estrogenic and antiestrogenic activity of toremifene (TOR), tamoxifen (TAM) and their metabolites to better understand the potential effects of cytochrome P-450 2D6 (CYP2D6) status on the activity of these drugs in ... |
|
|
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
J. Urol. 187(3) , 889-93, (2012) Whether race influences bone loss and fracture risk during androgen deprivation therapy for prostate cancer is unknown. Using data from a prospective clinical trial we compared bone mineral density and fracture between African-American and Caucasian men recei... |